Optimal treatment for malignant pleural mesothelioma (MPM) is still under investigation. Several treatment strategies have been used with very limited success. Recent studies have shown that some patients benefit from multimodality treatment including aggressive surgery, radiation, and chemotherapy.
1 x 1 Sugarbaker, DJ, Flores, RM, Jaklitsch, MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999; 117: 54–65 Abstract | Full Text | Full Text PDF | PubMed | Scopus (731) | Google Scholar See all References
, 2 x 2 Rusch, VW, Rosenzweig, K, Venkatraman, E et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001; 122: 788–795 Abstract | Full Text | Full Text PDF | PubMed | Scopus (363) | Google Scholar See all References
, 3 x 3 Rea, F, Marulli, G, Bortolotti, L et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. Lung Cancer. 2007; 57: 89–95 Abstract | Full Text | Full Text PDF | PubMed | Scopus (98) | Google Scholar See all References The multimodality treatment protocols have achieved a median survival of 19 to 46 months depending on the stage, histology, and completeness of the surgical resection.
1 x 1 Sugarbaker, DJ, Flores, RM, Jaklitsch, MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999; 117: 54–65 Abstract | Full Text | Full Text PDF | PubMed | Scopus (731) | Google Scholar See all References
, 2 x 2 Rusch, VW, Rosenzweig, K, Venkatraman, E et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001; 122: 788–795 Abstract | Full Text | Full Text PDF | PubMed | Scopus (363) | Google Scholar See all References
, 3 x 3 Rea, F, Marulli, G, Bortolotti, L et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. Lung Cancer. 2007; 57: 89–95 Abstract | Full Text | Full Text PDF | PubMed | Scopus (98) | Google Scholar See all References
, 4 x 4 Pagan, V, Ceron, L, Paccagnella, A et al. 5-year prospective results of trimodality treatment for malignant pleural mesothelioma. J Cardiovasc Surg (Torino). 2006; 47: 595–601 PubMed | Google Scholar See all References
, 5 x 5 Flores, RM, Zakowski, M, Venkatraman, E et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007; 2: 957–965 Abstract | Full Text | Full Text PDF | PubMed | Scopus (130) | Google Scholar See all References In a certain subgroup of patients with epithelial histology, no lymph node involvement and complete surgical resection the results were even more favorable with occasional long-term survival.
1 x 1 Sugarbaker, DJ, Flores, RM, Jaklitsch, MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999; 117: 54–65 Abstract | Full Text | Full Text PDF | PubMed | Scopus (731) | Google Scholar See all References